1/ Check out our recent publication in @JCardFail !
The Cardiac Amyloidosis Registry Study (CARS): Rationale, Design and Methodology - https://t.co/mYuUeD3Ms7
🔥 New in @JACCJournals#HF
❓prognostic role of p.V142I on race, genotype and outcomes in ATTR-CA
🔑 Black patients experienced a more advanced ATTR-CA phenotype irrespective of genotype
🔗https://t.co/kpw2idBv5J
Transthyretin amyloid cardiomyopathy characteristics have changed over the past 20 years. However, significant residual mortality still represents a significant unmet need.
https://t.co/hLPyjN94LS
#cardiotwitter
(1/14) 🚨I had the privilege of providing commentary on the Phase 2 #coramitug trial at #AHA25. The headline was that patients who received high-dose (60 mg/kg) coramitug had significant reductions in NT-proBNP at 1 year compared with placebo. So it’s an unequivocal win, right? The full story is a bit more complicated…🤔
More incredible #CRISPR data with #Nexz published today in @NEJM -- this time 2 year data from the Phase 1 #ATTR polyneuropathy study. #TTR levels down 90% by day 28... and 92% at month 24! Improved neuropathy functionally and by #Nfl levels. Exciting prospects for #MAGNITUDE. https://t.co/2tMKXtXx7B
1/2 We presented exploratory data from ATTRibute-CM looking at all events - CVM and recurrent CVH - which show early and sustained effect of acoramidis throughout the study.
#HFSA2025#CardioTwitter#MedIQHFSA2025
Proud to share our review on transthyretin amyloid cardiomyopathy! https://t.co/giACwEptSR
We break down the current treatments, what’s in the pipeline, and what’s next.
@UreyTony@UCSDCardiology
Presented this at #ISHLT2025: In our single-center study @SmidtHeart , pre- heart transplant sensitization & older donor age were associated with immediate presentation of severe PGD-LV ⚠️.
Immediate presentation = worse 30-day & 1-yr survival vs delayed presentation 📉.@ISHLT
ACC CardiaCast: Innovation in Action: 🆕 Podcast Series
ACC Chief Innovation Officer @AmiBhattMD is joined by Drs. @amey_vrudhula & @LilySternMD to delve into AI model training & how to leverage AI for early 🔎 of cardiac amyloidosis.
🎧 https://t.co/gWmPaExZMB #ACCInnovation
I am excited to share our recent publication @TheJHLT, demonstrating how therapeutic plasma exchange improves survival in patients experiencing severe primary graft dysfunction after heart transplantation.
Link: https://t.co/prdAxs9N0Z
Beyond grateful to my mentor, Dr.Kobashigawa, and the team @SmidtHeart for the support and guidance
🚨🚨🚨 MAJOR news in the #amyloidosis world this morning with positive topline results of #HELIOS-B. #Vutrisiran met all primary & secondary endpoints. Let's break down what we know... #StanfordAmyloidCenter (1/13)
Working with expert clinicians like @LilySternMD and @JigPatelMDPhD here at @SmidtHeart and similar amyloid specialists at the four sites, we are focused on bringing the right diagnoses to the right patients, and use AI facilitate timely and effective care.
https://t.co/K3dGIS1vSP
1/ Check out our recent publication in @JCardFail !
The Cardiac Amyloidosis Registry Study (CARS): Rationale, Design and Methodology - https://t.co/mYuUeD3Ms7